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Crystal Structure of the Glucocorticoid Receptor
Ligand Binding Domain Reveals a Novel Mode of
Receptor Dimerization and Coactivator Recognition
a therapeutically important target. GR ligands, including
dexamethasone, prednisolone, and other related corti-
costeroid analogs, are commonly used to treat diverse
medical conditions such as asthma, allergic rhinitis,
rheumatoid arthritis, and leukemia (Barnes et al., 1998).
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However, clinical use of oral corticosteroids is limitedMillard H. Lambert,2 John T. Moore,6
by a number of side effects ranging from increased boneKenneth H. Pearce,1,8 and H. Eric Xu2,8,10
loss and growth retardation to suppression of the hypo-1Gene Expression and Protein Biochemistry
thalamic-pituitary-adrenal axis. Discovery of a GR ago-2 Computational, Analytical and Structural Sciences
nist that retains the beneficial anti-inflammatory activi-4 Nuclear Receptor Systems Research
ties without the undesired side effects is the subject of5 High Throughput Chemistry
intense pharmaceutical efforts.6 High Throughput Biology
GR belongs to the nuclear receptor (NR) superfamily,Discovery Research
which includes receptors for the mineralocorticoidsGlaxoSmithKline
(MR), estrogens (ER), progestins (PR), and androgensResearch Triangle Park, North Carolina 27709
(AR), as well as receptors for peroxisome proliferators7 Gene Expression and Protein Biochemistry
(PPARs), vitamin D (VDR), and thyroid hormones (TR).Discovery Research
Phylogenetic analysis and sequence alignments showGlaxoSmithKline
that GR, MR, PR, and AR form a subfamily of oxosteroidStevenage SG1 2NY
receptors that are distinct from the ER subfamily (NRNC,United Kingdom
1999). Like most nuclear receptors, GR is a modular
protein that is organized into three major domains: an
N-terminal activation function-1 domain (AF-1), a centralSummary
DNA binding domain (DBD), and a C-terminal ligand
binding domain (LBD). In addition to its role in ligandTranscriptional regulation by the glucocorticoid re-
recognition, the LBD contains a ligand-dependent acti-ceptor (GR) is mediated by hormone binding, receptor
vation function (AF-2) that is tightly regulated by hor-dimerization, and coactivator recruitment. Here, we
mone binding.report the crystal structure of the human GR ligand
Within the context of the full-length receptor, both thebinding domain (LBD) bound to dexamethasone and
AF-1 function and the DNA binding activity of GR are
a coactivator motif derived from the transcriptional
dependent on hormone binding. In the absence of li-
intermediary factor 2. Despite structural similarity to gand, GR is retained in the cytoplasm by association
other steroid receptors, the GR LBD adopts a surpris- with chaperone proteins such as hsp90 and p23, which
ing dimer configuration involving formation of an inter- bind to the LBD (Pratt and Toft, 1997). The chaperone
molecular  sheet. Functional studies demonstrate that activity of the hsp90 complex has been shown to be
the novel dimer interface is important for GR-mediated critical for hormone binding by GR (Bresnick et al., 1989;
activation. The structure also reveals an additional Picard et al., 1990). Hormone binding initiates the release
charge clamp that determines the binding selectivity of chaperone proteins from GR, allowing dimerization
of a coactivator and a distinct ligand binding pocket and translocation of the receptor into the nucleus. In
that explains its selectivity for endogenous steroid the nucleus, GR binds to DNA promoter elements and
hormones. These results establish a framework for can either activate or repress transcription depending
understanding the roles of protein-hormone and pro- on the context of the target promoters. In addition, GR
tein-protein interactions in GR signaling pathways. can also crosstalk with other transcriptional factors such
as nuclear factor-B (NF-B) and activator protein-1
(AP-1) to repress their gene activation activities (re-Introduction
viewed in McKay and Cidlowski, 1999). This GR medi-
ated repression has been postulated to be a molecularThe glucocorticoid receptor (GR) is a steroid hormone-
basis for the anti-inflammatory and immunosuppressiveactivated transcriptional factor known to regulate, either
activities of glucocorticoids. Both the ligand-dependentdirectly or indirectly, target genes involved in glucose
activation and repression by GR require the intact func-homeostasis, bone turnover, cell differentiation, lung
tion of the LBD.maturation, and inflammation (Reichardt et al., 2000).
The molecular mechanism of ligand-dependent regu-Mutations in GR are associated with Cushing’s syndrome,
lation of nuclear receptors has been illustrated by crystalautoimmune diseases, and various cancers (Werner and
structures of more than a dozen NR LBDs that are eitherBronnegard, 1996). As such, GR is widely recognized as
in the apo-state or bound to agonists or antagonists.
(Bourguet et al., 1995; Brzozowski et al., 1997; Renaud
8 Correspondence: eric.xu@vai.org (H.E.X.); kenneth.h.pearce@gsk.
et al., 1995; Wagner et al., 1995; Xu et al., 1999). Thesecom (K.H.P.)
structures not only reveal that the LBDs fold into a ca-9 These authors contributed equally to this work.
nonical three-layer helical sandwich that embeds a hy-10 Present address: Laboratory of Structural Sciences, Van Andel
Research Institute, 333 Bostowick NE, Grand Rapids, Michigan. drophobic pocket for ligand binding, but also highlight
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the importance of the C-terminal (AF-2) helix in ligand- dimer interface unlike that observed for any other nuclear
dependent regulation. In the apo- or antagonist-bound receptor. Mutagenesis studies support the importance
receptor, the AF-2 helix is destabilized from its “active” of this dimer interface in GR function. The crystal struc-
conformation to allow the LBD to interact with corepres- ture also reveals an unanticipated second charge clamp
sors such as nuclear corepressor (N-CoR) and silencing that is responsible for the specificity for the third TIF2
mediator for retinoid and thyroid hormone receptors LXXLL motif, and a distinct steroid binding pocket with
(SMRT; Chen and Evans, 1995; Horlein et al., 1995). features that explain ligand binding and selectivity.
Agonist binding induces a conformational change of the Since GR is highly homologous to MR, AR, and PR, the
AF-2 helix, stabilizing the receptor in an active confor- structure presented here should serve as a model for
mation to facilitate its association with coactivator pro- understanding the roles of ligand binding, coactivator
teins, such as steroid receptor coactivator-1 (SRC-1) recruitment, and receptor dimerization in the signaling
and transcriptional intermediary factor 2 (TIF2; Onate et pathways mediated by these steroid receptors.
al., 1995; Voegel et al., 1996). These coactivators contain
multiple LXXLL motifs, which interact with the NR LBD Results
(Heery et al., 1997; Le Douarin et al., 1996). Various
crystal structures of receptor/coactivator peptide com- Purification, Characterization, and Crystallization
plexes have revealed a general mode of coactivator of the GR LBD
binding to NRs. In these structures, the coactivator Historically, the GR LBD has been a very difficult protein
LXXLL motifs adopt a two-turn  helix and both helical to express in a recombinant form mostly due to solubility
ends are stabilized by a “charge clamp” formed in part problems. We were also unsuccessful in our own at-
by a conserved acidic residue from the AF-2 helix (Dari- tempts to express the wild-type human GR LBD at high
mont et al., 1998; Nolte et al., 1998; Shiau et al., 1998). levels even though a wide range of conditions were
However, the structural basis for the sequence specific explored. To overcome these difficulties, we performed
recruitment of LXXLL motifs by different LBDs has re- a sequence alignment of GR with the related steroid
mained ambiguous. receptors PR and AR, which have been previously ex-
As DNA binding transcription factors, most NRs func- pressed and purified from E. coli (Matias et al., 2000;
tion as dimers. Receptor dimerization is mediated in Sack et al., 2001; Williams and Sigler, 1998). This analy-
part through the LBD. Crystal structures of the ER homo- sis was initiated to identify residues that are hydropho-
dimer and two different RXR heterodimers reveal a com- bic in GR but hydrophilic in PR and AR as they might
mon mode of dimerization, where the N-terminal half of contribute to solubility or aggregation problems. We
helix-10 from one monomer packs against the same also built a structural model for GR by using its homology
portion of helix-10 from the other monomer in a parallel to the PR LBD to explore the molecular basis of the
manner (Bourguet et al., 1995; Gampe et al., 2000). The poor behavior of the GR protein and to prioritize residues
dimerization is mediated through a sequence motif of for systematic mutagenesis. Strikingly, we found that a
φ φKφφ φKφφ X φRφφ (where φ is a hydrophobic single phenylalanine to serine mutation in helix 5 (F602S)
residue and X is any residue) that forms a coiled-coil
significantly improved E. coli expression of a soluble
structure in the N-terminal half of helix-10. Mutations in
GR LBD (residues 521–777) in the presence of dexa-
theφKφφ repeats in ER that abolish dimerization result
methasone (Figure 1A). This point mutant LBD was puri-
in a receptor that is defective for initiating of gene tran-
fied to homogeneity for biochemical and structural stud-scription (Valentine et al., 2000). Like ER, GR and its
ies described below.related receptors AR and PR, activate transcription as
To assess the functional activity of the purified GRhomodimers and the GR LBD alone has been shown to
LBD, we used a fluorescence polarization assay to testbe capable of forming a homodimer (Savory et al., 2001).
the binding of a fluorescently labeled dexamethasoneThe dimer interface observed in the PR LBD structure
derivative to the receptor. In this experiment, we at-does not involve helix-10 and is significantly smaller
tempted to remove the excess dexamethasone carriedthan that seen in the RXR heterodimer or in the ER
over from purification by extensive dialysis. Figure 1Bhomodimer (Williams and Sigler, 1998). The physiologi-
shows that this dialyzed GR LBD exhibits dose-depen-cal relevance of this PR dimer interface remains to be
dent saturable binding to the fluorescent dexametha-determined. To date, the arrangement of the GR LBD
sone derivative with an apparent affinity of 60 nM. Addi-dimer has not been defined. In the full-length receptor,
tion of excess unlabeled dexamethasone completelyGR contains an additional homodimer interface on the
inhibited the binding signal of the labeled dexametha-C-terminal end of the DBD. Interestingly, a mutation
sone derivative.(A458T) in this region of mouse GR, termed GRdim, is
Dexamethasone is a potent agonist that promotes thedefective in transcription activation but not transrepres-
binding of coactivators to GR (Ding et al., 1998). Tosion (Reichardt et al., 1998).
test the ability of the dexamethasone-bound GR LBDGiven its biological and pharmaceutical importance,
to recruit coactivators, we used surface plasmon reso-there has been enormous interest in elucidating the GR
nance to measure the interaction of the receptor withLBD structure. However, these structural efforts have
a peptide containing the third LXXLL motif from TIF2been hampered by the inability to obtain a purified re-
(Voegel et al., 1998). TIF2 is the human homolog of theceptor that retains ligand binding activity. In this paper,
mouse GR interacting protein 1 (GRIP1) and its thirdwe describe expression, purification, crystallization, and
LXXLL motif has been shown to be preferred by GRstructure determination of the GR LBD in complex with
(Ding et al., 1998). Figure 1C shows that addition of adexamethasone and a coactivator motif derived from the
cofactor TIF2. Surprisingly, the structure reveals a novel 5-fold excess of dexamethasone enhances the binding
Crystal Structure of the Glucocorticoid Receptor
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Figure 1. Purification and Characterization
of the GR LBD
(A) Comparison of the protein expression of
wild-type GR (lane 1) and the F602S GR (lane
2) in the presence of 10 M dexamethasone.
The proteins shown are the soluble fractions
eluted from the Ni2 column. Lanes 3–5 show
the purification of the F602S GR LBD (lane 3,
the sample after thrombin digestion; lane 4,
the Ni2 column flow through of the thrombin-
digested sample; lane 5, the final purified pro-
tein. The molecular weight markers are shown
in lane M and the 6  HisGST-fused and
cleaved GR LBD are indicated with a star and
an arrow, respectively.
(B) Binding of dexamethasone to the purified
GR F602S proteins as measured by fluores-
cence polarization assays (circles: GST-GR
LBD; triangles: GR LBD; and squares: GR
LBD in the presence of 100 M unlabeled
dexamethasone).
(C) Ligand-dependent binding of TIF2 coacti-
vator motif to GST-GR LBD in the presence of
a 5-fold excess of dexamethasone (triangles),
RU486 (squares), and no compound (circles)
was measured by surface plasmon reso-
nance.
(D) Crystals of the GR/Dex/TIF2 complex.
of the TIF2 coactivator peptide to the purified and dia- resembling the structures of PR and AR (Matias et al.,
2000; Sack et al., 2001; Williams and Sigler, 1998). Heli-lyzed GR LBD. In contrast, addition of a 5-fold excess
of RU486, a known GR antagonist, inhibited the binding ces 1 and 3 form one side of a helical sandwich whereas
helices 7 and 10 form the other side. The middle layerof the receptor to the TIF2 peptide. These results dem-
onstrate that the purified GR LBD is able to bind either of helices (helices 4, 5, 8, and 9) are present in the top
half of the protein but are absent in the bottom half ofan agonist or an antagonist in the absence of the hsp90
chaperone. Importantly, the ligand-mediated associa- the protein. This arrangement of helices creates a cavity
in the bottom half of the GR LBD where the dexametha-tion of the TIF2 peptide to the purified GR correlates
with the agonist and antagonist properties of dexameth- sone molecule is bound. The AF-2 helix, which plays an
essential function in ligand-dependent activation, adoptsasone and RU486. Based on these results, a ternary
complex of the purified GR LBD bound with dexametha- the so-called “agonist bound” conformation where it
packs against helices 3, 4, and 10 as an integrated partsone and the TIF2 peptide was prepared and crystallized
(Figure 1D).
Table 1. Statistics of Crystallographic Data and Structures
Structure of the GR/Dexamethasone/
Crystals 1 2TIF2 Complex
The GR/dexamethasone/TIF2 complex was crystallized X-ray Source Rigaku-200 APS-17BM
space group P61 P61in the P61 space group with two complexes in each
resolution (A˚) 20.0–2.8 50.0–2.5asymmetric unit. Data sets were collected from two in-
unique reflections 18,923 27,095dependent crystals to 2.8 A˚ and 2.5 A˚, respectively. We
completeness (%) 99.7 99.4determined both structures by the molecular replace-
I/ (last shell) 25.7 (2.3) 35.9 (2.5)
ment method using a GR model built from the PR LBD Rsyma (%) 8.5 8.2
structure (see Experimental Procedures). The electron
Refinement statisticsdensity map calculated with the molecular replacement
R factorb (%) 25.4 23.7
solutions showed clear tracing for two GR LBD mono- R free (%) 30.8 26.7
mers (residues 523–777), two bound molecules of dexa- rmsd bond lengths (A˚) 0.015 0.007
methasone, and the LXXLL motifs of the two TIF2 pep- rmsd bond angles (degrees) 1.800 1.500
total non-hydrogen atoms 4502 4845tides. The statistics of data sets and the refined
structures are summarized in Table 1. rmsd is the root mean square deviation from ideal geometry.
In the crystals, each GR LBD is bound to a molecule a Rsym   | Iavg 	 Ii|/ Ii
b Rfactor  |FP 	 FPcalc |/FP, where FP and Fpcalc are observed andof dexamethasone and a TIF2 coactivator peptide (Fig-
calculated structure factors, Rfree was calculated from a randomlyure 2A). The structure of the GR LBD contains 11 
chosen 10% of reflections excluded from refinement and Rfactor washelices and 4 small 
 strands that fold into a three-
calculated for the remaining 90% of relfections.
layer helical domain with an overall organization closely
Cell
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Figure 2. Structure of the GR/Dex/TIF2
Complex
(A) Overall arrangement of the GR LBD dimer.
The two LBDs are shown in yellow and blue
worms; the two TIF2 peptides are in purple
ribbon; and the two dexamethasone mole-
cules are in space-filling representation with
carbon, oxygen, and hydrogen colored in
green, red, and white, respectively. The C2
symmetry axis is shown in red.
(B and C) Two 90-degree views of the GR/
Dex/TIF2 monomer complex, where helices
are colored in yellow and 
 strands are in
gold. The AF-2 helix is in red and the lysine
residue from helix 3 that forms the charge
clamp is in blue. The TIF2 peptides are shown
in purple.
of the domain structure. Following the AF-2 helix is an the extended strand between helices 1 and 3 (residues
547–551) and the last residue of helix 5 (Q615). In particu-extended strand that forms a conserved 
 sheet with a

 strand between helices 8 and 9. This C-terminal 
 lar, residues 547–551 from each LBD, resembling two
anti-parallel 
 strands, are in excellent geometry to formstrand also appears to play an important role in receptor
activation by stabilizing the AF-2 helix in the active con- four hydrogen bonds (Figure 3C). These hydrogen bonds
may also play a key role in stabilizing the GR dimerformation. Deletion of the last few residues that form
the 
 strand resulted in an inactive receptor (Zhang et configuration.
To confirm the presence of dimeric GR LBD in solu-al., 1996).
tion, we analyzed the distribution of monomers and di-
mers in the GR population by equilibrium analytical ultra-The GR Dimer Interface
Strikingly, the two GR LBD monomers in each asymmet- centrifugation. In the presence of both dexamethasone
and the TIF2 peptide, a clear monomer-dimer equilib-ric unit are arranged in a unique dimer configuration.
Unlike the asymmetric arrangement of the PPAR/RXR rium was observed with an apparent dimerization affinity
(Kd) of 1.5 M (Figure 4A). We further confirmed theheterodimer structures (Gampe et al., 2000), the two GR
monomers show a C2 symmetric packing arrangement presence of the GR dimer in solution by dynamic light
scattering. In this experiment, the PPAR/RXR hetero-in which either LBD can be superimposed on the other
by rotating 180 degrees around the 2-fold axis (Figure dimer was used as a positive control with a measured
hydrodynamic diameter of 84 A˚, which is consistent with2A). Formation of the dimer buries 623 A˚2 of solvent
accessible surface in the dimer interface, which is also the actual size of the heterodimer observed in PPAR/
RXR crystal structure (Gampe et al., 2000). The hydrody-stabilized by a series of hydrophobic and hydrogen bond
interactions (Figure 3A). The central hydrophobic inter- namic diameter of the GR LBD complex was measured
to be 82 A˚, which is also closely correlated with the sideface is made up of reciprocal interactions between resi-
dues P625 and I628 in the 
 turn of strands 3 and 4 to side distance of 83–88 A˚ observed in the GR dimer
structure.(Figure 3B). Surrounding this core hydrophobic interface
is an extensive network of hydrogen bonds mediated by Since P625 and I628 make up the core hydrophobic
Crystal Structure of the Glucocorticoid Receptor
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Figure 3. Characterization of the GR Dimer Interface
(A) The GR dimer interface showing the key residues and the pseudo

 strands (bottom). The I628 and P625 are labeled for the two LBDs
(colored in yellow and blue, respectively).
(B) The core hydrophobic interactions between the two GR LBDs.
The I628 and P625 are both labeled for the blue monomer.
(C) The hydrogen bond network between the pseudo 
 strands.
dimer interface, these residues were mutated to alanine
within the context of the F602S mutant to test their role
in LBD-LBD dimerization. The P625A/F602S LBD protein
was insoluble in E. coli and was not useful for biochemi-
cal studies. However, the I628A/F602S GR LBD is nearly
as soluble as the F602S LBD (Figure 4B) and was purified
to homogeneity for in vitro characterization (lane 7 in
Figure 4B). As measured by analytical ultra-centrifuga-
tion, the I628A/F602S mutant LBD showed a 10-fold
decrease in dimerization affinity as compared to the
F602S GR LBD (Figure 4A). These results demonstrate Figure 4. Functional roles of the GR Dimer Interface
that the GR LBD forms a dimer in solution and the inter- (A) Dimer-monomer distributions of the F602S GR LBD (circles) and
face observed in the crystal structure is required for the I628A/F602S LBD (triangles) as analyzed by analytic ultra-cen-
trifugation.effective dimerization.
(B) Comparison of the protein solubility of the P625A/F602S mutant
(lanes 3–4) and the I628A/F602S mutant (lanes 5–6) with the F602S
Functional Analysis of GR Dimer Interface mutant (lanes 1–2). Lanes 1, 3, and 5 represent pellet fractions and
lanes 2, 4, and 6 represent soluble fractions. The purified I628A/To test the functional significance of the dimer interface
F602S mutant LBD is shown in lane 7 with molecular weight markersobserved in the GR LBD, we mutated P625 and I628 to
indicated (lane M in Kd).alanine within the context of the full-length receptor. We
(C) Transactivation and transrepression by the wild-type and mutantcharacterized these mutants in a transient transfection
GRs, where the I628A and P625A mutations are made in the dimer
assay using a reporter driven by the MMTV promoter. interface. The EC50 of dexamethasone for wild-type, F602S, I628A,
In the presence of dexamethasone, the wild-type and and P625A receptors is 26, 28, 400, and 2000 nM, respectively. The
full level of activation by the P625A mutant is only 5% of wild-type.the F602S mutant receptors induced 46.0-fold and 46.8-
(D) Western blots showing the expression of GR.fold activation, respectively (Figure 4C). The P625A and
I628A mutant proteins were expressed at levels compa-
rable to wild-type (Western blot in Figure 4D), but both
showed a 3- to 5-fold decrease in fold of activation as activation by NF-B. In this assay, we used a reporter
driven by the promoter from the monocyte chemoattrac-compared with the wild-type. Furthermore, the absolute
magnitude of activation by the P625A mutant is only 5% tant protein-1 (MCP-1), which is a well-characterized
NF-B activated gene (Ping et al., 1999). In contrast toof wild-type. The results with the P625A mutant are
consistent with a previous study where the analogous the transactivation assay, GR with the I628A mutation
repressed the MCP-1 promoter activity to the same ex-rat GR mutant (P643A) was also defective in transactiva-
tion (Caamano et al., 1998). Together, these results es- tent as the wild-type or the F602S receptor (Figure 4C).
However, the P625A mutant was inactive in this assay.tablish that residues comprising the dimer interface are
important for the GR transactivation function. This defect in activity of the P625A mutant in both assays
is consistent with previous studies that indicated thatWe also tested the ability of the GR mutants to inhibit
Cell
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Figure 5. Structural Basis for the Specificity
of Coactivator Motifs
(A) A superposition of the TIF2 third motif
(purple) with the SRC-1 motif (green) on the
surface of the GR coactivator binding site,
where color is based on atom types (carbons:
white, sulfur: yellow, nitrogen: blue and oxy-
gen: red). The hydrogen bonds between the
TIF2 residues (R2 and D6) and the GR
residues (D590 and R585) that form the sec-
ond charge clamp are indicated by green
dashed lines.
(B) Sequences of the second and third coacti-
vator motifs in TIF2, and the mutated peptide
M32, where the charged residues R2 and
D6 in the third motif have been replaced
with the corresponding residues from the
second motif, H2 and Q6.
(C) Conservation of amino acids in the second
charge clamp. Sequence alignment of GR,
AR, PR, and MR with arrows indicating the
residues that form the second charge clamp.
(D) Effects of the R2H and D6Q mutation
(the M32 peptide) on the binding of the co-
activator motifs to GR, PR, AR, and ER
.
Dose inhibition curves are shown for the bind-
ing of the TIF2 third motif (circles) and the
mutated third motif (squares) with control
curves of DMSO (triangles). Compared with
the wild-type TIF2 third motif, the mutated
motif decreases its affinity to GR, AR, and PR
by 15- to 50-fold, but has little effect (2-fold) on binding to ER
.
(E) Effects of the second charge clamp mutations (R585A and D590A) on the activation mediated by the GR LBD, as compared with the wild-
type GR LBD or the mutations in the first charge clamp from the AF-2 helix (E755A or E755R).
the analogous rat mutation (P643A) did not translocate bonds between the second GR charge clamp and the
TIF2 coactivator by mutating the residues at the 2properly to the nucleus in the presence of ligand (Ca-
and 6 positions of the third LXXLL motif. Replacingamano et al., 1998). Importantly, the contrasting effects
these two residues in the third motif with correspondingof I628A on transactivation versus transrepression sug-
residues from the second motif decreased binding togest that the monomer and dimer forms of GR may
GR (Figure 5D). Therefore, the hydrogen bonds formedregulate distinct signaling pathways.
with the second charge clamp contribute to the selective
binding of the third TIF2 LXXLL motif. We also directly
Recognition of the TIF2 LXXLL Motif addressed the role of the second charge clamp by mu-
Coactivators such as SRC-1 and TIF2 contain three tating the two charged residues D590 and R585 to ala-
LXXLL motifs, and all previous crystal structures of LBD/ nine within the context of a GAL4-GR LBD chimeric
coactivator complexes were solved with the first or the receptor. The fusion protein of the wild-type GR LBD
second LXXLL motif. The GR LBD/TIF2 complex is the with the GAL4-DBD induced 5-fold activation of the re-
first structure with the third LXXLL motif, and it provides porter driven by the GAL4 DNA binding sites (Figure 5E).
an unexpected explanation for the preferential binding Mutations either in the first charge clamp (E755 on the
of this motif to the receptor (Ding et al., 1998). In the AF-2 helix) or the second charge clamp (residues R585
GR LBD structure, the LLRYLL sequence in the TIF2 and D590) dramatically reduced the activation mediated
motif forms a two-turn  helix that orients the hydropho- by the GR LBD, demonstrating that both charge clamps
bic leucine side chains into a groove formed in part by are critical for transactivation in vivo.
the AF-2 helix and residues from helices 3, 3, 4 , and 5 The residues (D590 and R585) comprising the second
(Figure 2). The N- and C-terminal ends of the coactivator charge clamp in GR are conserved in PR and AR but
helix are clamped by E755 from the AF-2 helix and K579 not in ER (Figure 5C). Mutations in the third TIF2 LXXLL
in helix 3, respectively. The docking mode of the TIF2 motif that alter the second charge clamp dramatically
LXXLL motif is similar to that seen in the coactivator reduce affinity to AR and PR, similar to the result ob-
complexes of RXR, ER, TR, PPAR, and PPAR (Dari- tained with GR. These data suggest that the subfamily
mont et al., 1998; Gampe et al., 2000; Nolte et al., 1998; of oxosteroid receptors may share a common mecha-
Shiau et al., 1998; Xu et al., 2001). However, unexpect- nism of coactivator selectivity (Figure 5D). In contrast,
edly, the GR residues D590 and R585 form a second these TIF2 mutations have little effect on binding to ER.
charge clamp that interacts with residues R2 and D6
(Figure 5A), which are only present in the third LXXLL Recognition of Dexamethasone
motif of coactivators (Figure 5B). In the crystal structure, dexamethasone is completely
enclosed within the bottom half of the GR LBD (FigureWe addressed the functional role of the hydrogen
Crystal Structure of the Glucocorticoid Receptor
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Figure 6. Molecular Basis of Ligand Recog-
nition by GR
(A) Ligand binding pocket of GR and its com-
parison with the pockets of AR, PR, and ER.
GR is colored in yellow in all three overlays.
(B) Electron density map showing dexameth-
asone and the surrounding residues in GR.
The map is calculated with 2Fo-Fc coeffi-
ciency and is contoured at one .
(C) Schematic representation of GR/dexa-
methasone interactions. Hydrogen bonds
and hydrophobic interactions are indicated
by solid arrows and dashed lines, respec-
tively. A possible weak hydrogen bond be-
tween C736 and the C20 ketone is omitted
for clarity.
(D) Chemical structures of the endogenous
steroid hormones and the numbering of the
rings and key atoms.
2B). The ligand binding pocket is composed of residues observed here are likely to contribute to the high affinity
binding of dexamethasone.from helices 3, 4, 5, 6, 7, 10, and the AF-2 helix as
well as residues from the 
 strands 1 and 2. Strikingly, Interestingly, dexamethasone also makes direct con-
tacts with the AF-2 helix (L753) and the loop precedingcompared with the steroid-shaped pocket found in the
PR, AR, or ER structures, the GR pocket has an addi- the AF-2 helix (residues I747 and F749). These interac-
tions are likely to stabilize the AF-2 helix in the activetional branch extending from the center in the side of
the steroid pocket. This additional side pocket in GR is conformation, and may serve as a molecular basis for
ligand-dependent activation of GR.formed by the structural rearrangement of helices 6 and
7 (Figure 6A).
The binding mode of dexamethasone can be deter- Discussion
mined unambiguously by the clear electron density (Fig-
ure 6B). The ligand is oriented with its A ring toward the A longstanding problem for GR structural studies has
been the expression and purification of an active protein.
 strands 1 and 2 and its D-ring toward the AF-2 helix.
The volume of the GR pocket is approximately 599 A˚3 Here, we have overcome this problem by using a single
point mutation, F602S, in the GR LBD. This single muta-in subunit A and 578 A˚3 in subunit B. Although dexameth-
asone occupies only 65% of the volume, the high affinity tion resulted in robust expression of a soluble GR LBD
and ultimately allowed us to solve its crystal structure.binding of dexamethasone to GR is readily explained by
the extensive hydrophobic and hydrophilic interactions The structure revealed a novel dimer interface, a unique
steroid binding pocket, and a second charge clamp re-between the ligand and the protein (Figure 6C). One
or more hydrophobic residues within the GR protein sponsible for sequence specific binding of a coactivator
protein. These structural observations provide criticalcontact nearly every atom of the steroid core of dexa-
methasone. insights into the protein-ligand and protein-protein inter-
actions that control the GR signaling pathways.In addition, all of the hydrophilic groups of dexametha-
sone form hydrogen bonds with the protein. As shown
in Figure 6C, the A ring carbonyl forms direct hydrogen Important Role of the GR Dimer
The GR LBD in the crystal is packed as a symmetricbonds to the guanidinium of R611 and to the -amide of
Q570. The side chain of N564 is oriented in a way to allow dimer, which is consistent with biochemical data show-
ing that the GR LBD can form a homodimer or a hetero-it to make hydrogen bonds to the C ring 11-hydroxyl
and 24-hydroxyl. Furthermore, the 21-hydroxyl (off the dimer with the closely related MR LBD. These earlier
studies, however, failed to identify the position or theC17 position) and the 22-carbonyl form hydrogen bonds
with residues Q642 and T739, respectively. The exten- configuration of the GR dimer interface (Savory et al.,
2001). The crystallographically observed GR LBD dimersive hydrogen bond network between GR and the ligand
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interface is strikingly different from the helix-10 dimer ous study in which the rat GR with the corresponding
interface observed in the previous ER homodimer or mutation P643A was defective in transactivation (Ca-
RXR heterodimer structures. Structure based sequence amano et al., 1998). Although the P643A rat GR retained
alignments reveal that RXR and its heterodimer partners normal ability to bind DNA, it showed decreased stability
have a consensus dimerization motif ofφ AKφφφKφφ for heterocomplex formation with hsp90. Since P625 is
X φRφφ that forms a coiled-coil structure in the first the central dimerization residue, this would suggest that
half of H10 (Gampe et al., 2000). ER and HNF4 have the the GR dimerization interface might overlap the hsp90
same φXφφ repeats that allow them to form homodi- binding site.
mers but lack the basic residues in the X position re- Compared with the large interface observed in the
quired for heterodimerization. However, GR and its re- RXR dimer structures, the GR LBD dimerization inter-
lated receptors, PR and AR, have a sequence of F YQLT face is much more limited, reflecting its weaker dimer-
KLLD S MHEV in the corresponding H10 region that is ization affinity (Kd 1.5 M for GR versus 110 nM for
not able to form a coiled-coil structure due to the devia- RXR dimers). In the context of the full-length receptor,
tion of the underlined residues from theφXφφ repeats. the low dimerization affinity of the GR LBD can be com-
Furthermore, in the GR structure, the extended C-ter- pensated by an additional interface found in the DNA
minal strand packs against the N terminus of H10 and binding domain and possibly the hinge region preceding
would further block the dimer configuration seen in the the LBD (Savory et al., 2001). Several reports have high-
ER and RXR structures (Figure 2B). The difference in lighted the role of residues in the D loop of the DNA
the dimer interface between GR and ER may support binding domain for stabilizing receptor dimers (Luisi et
the evolutionary divergence of ER from the oxosteroid al., 1991; Reichardt et al., 1998). Normal GR functions
nuclear receptors (Escriva et al., 2000). require integrity of both interfaces as a mutation in the
We have also confirmed the functional significance of dimer interface in the DNA binding domain also abol-
the GR dimer interface by mutagenesis studies. Muta- ishes GR transactivation function (Reichardt et al., 1998).
tions in the two interface residues P625 and I628 com- The discovery of the novel dimer interface in the LBD
promise the GR transactivation function, but show dif- should provide additional ways to address the functional
ferent phenotypes in transrepression. While the P625A role of GR dimerization by genetic manipulations.
GR is completely inactive in repression, the I628A mu-
tant is as competent as the wild-type receptor. Using Coactivator Recognition by the Second
the purified I628A mutant protein, we have confirmed Charge Clamp
that this mutation decreases the LBD-LBD dimerization Nuclear receptors recruit coactivators primarily through
affinity. The phenotype of the I628A mutant is similar to the core LXXLL motifs. The fact that there are a large
that observed with the mouse GRdim mutant, which number of coactivators and each contains multiple LXXLL
shows that a defect in DBD dimerization results in loss of motifs poses a question of how specific recruitment of
GR activation function without affecting transrepression coactivators is achieved by a given nuclear receptor. Our
activity (Reichardt et al., 1998). structure reveals that GR uses two charge clamps to
The GR LBD contains multiple functions including li-
define its sequence specific binding to the TIF2 third
gand binding, chaperone association, nuclear location,
motif. The first charge clamp is composed of E755 from
transcription regulation, and others. These functions are
the AF-2 helix and K579 from helix-3, which cap the
interconnected and are highly dependent on the integ-
backbone amides and carbonyls of the coactivator helix.rity of the three-dimensional structure of the LBD. It is
Both residues that form the first charge clamp are highlypossible that the phenotype of the I628A mutant can be
conserved across members of the NR superfamily andattributed to other functions of the LBD in addition to
dictate a common binding mode for all LXXLL motifs.its effect on dimerization. We have found that the I628A
The second charge clamp is composed of R585 andmutant LBD requires a 20-fold higher concentration of
D590, which form hydrogen bonds with the side chainsdexamethasone to achieve full activation as compared
of the residues R2 and D6 that are present in theto the wild-type receptor (data not shown). However,
TIF2 third motif but not in its first or second motif. Thesethe I628A mutant is still competent for nuclear localiza-
interactions with the second charge clamp are responsi-tion and transrepression function at the same ligand
ble, in part, for the binding specificity of GR for the TIF2concentration used for activation of the wild-type recep-
third motif. Our results are consistent with the observa-tor. Thus, a mutation in the dimer interface can selec-
tion that the binding specificity of this motif is encom-tively decrease the potency for transactivation by the
passed within the TIF2 sequence of KENALLRYLLDKDDGR LBD.
(Darimont et al., 1998). The residues from the secondThe different phenotypes of the I628A and P625A mu-
charge clamp are conserved in the oxosteroid receptorstants may be attributed, in part, to the behavior of their
GR, AR, PR, and MR but are not present in ER or RXR-proteins. P625 is located in the 
-turn between two 

obligate heterodimers, such as PPAR. Thus, the secondstrands and is conserved among steroid receptors. It is
charge clamp may account for the differential binding oflikely that the P625A mutation disrupts the 
-turn, thus
coactivator motifs by many nuclear receptors. Notably,reducing the protein stability. Although in vivo, expres-
only the second LXXLL motif is required to mediate ERsion of the full-length receptor either with I628A or
transactivation while PPAR requires both the first andP625A appears to be similar (Figure 4D), the P625A
the second motifs. Since proteins like SRC-1 and TIF2mutant LBD is much less soluble than the I628A mutant
function as promiscuous coactivators, the existence ofin E. coli (Figure 4B). The P625A mutant also shows
three LXXLL motifs within their sequence may allowdefects in nuclear translocation upon ligand binding
(data not shown). Our results are consistent with a previ- them to integrate signaling pathways across multiple
Crystal Structure of the Glucocorticoid Receptor
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Figure 7. Basis for the GR Mutations
(A) The locations of natural GR mutations are
represented as Van der Waals spheres in the
overall structure. Green mutations are the
residues that contact dexmethasone directly
in the structure and the white mutations are
in the residues that form the hydrophobic
core of the protein. The side chain of S602 is
also presented.
(B) Hydrogen bond network mediated by the
S602 in the F602S mutant (balls and sticks)
and nearby water molecules (red spheres) in-
side of the protein.
NRs. Alternatively, as yet undiscovered coactivators The selectivity of GR ligands with larger substituents at
the C17 position can be best explained by the largermay exist that modulate GR signal transduction through
selective interactions with the second charge clamp. GR-side pocket. However, as discussed above, MR pre-
sumably has a similar pocket to GR. The selectivity of
MR for mineralocorticoids can be attributed to the differ-Hormone Selectivity by Steroid Receptors
Endogenous steroid hormones such as cortisone, tes- ences in hydrogen bonding patterns between the recep-
tor and the ligands. In fact, the MR selective steroids,tosterone, or progesterone share a similar core chemical
structure (Figure 6D) but mediate distinct biological re- corticosterone, aldosterone, and 11-deoxylcorticoste-
rone, all lack the 17-hydroxyl group, which forms asponses. Structural comparisons of GR, AR, PR, and
ER have provided insight into how functional specificity specific hydrogen bond with Q642 in the GR structure.
At this position, MR has a hydrophobic leucine (L848)is achieved by the steroid receptors. These steroid re-
ceptors share over 50% identity in their amino acid se- that would disfavor the presence of a polar hydroxyl in
this region. Together, the steroid selectivity appears toquences and a similar three-dimensional structure. In
these structures, the core steroid template (A, B, C, and be achieved by the complementarity of shape and hy-
drogen bonding between ligands and the ligand bindingD rings) assumes a common orientation with the A ring
oriented toward the conserved arginine from helix-5 and pockets in the receptors
the D ring toward the AF-2 helix. However, many subtle
differences in the secondary structure and the topology Naturally Occurring Mutations in the GR LBD
Missense mutations in the GR LBD have been associ-of the ligand binding pockets exist in these steroid re-
ceptors. In particular, helices 6 and 7 of GR deviate ated with a number of diseases, such as Cushing’s syn-
drome, autoimmune diseases, and various cancers, andsignificantly from ER, AR, and PR and produce a unique
side pocket in GR (Figure 6A). This pocket may account the impact of these mutations can readily be explained
by our structure. Based on the location in the GR struc-for the GR selectivity of glucocorticoids, which have
larger substituents at the C17 position compared with ture (Figure 7A), these mutations can be classified into
two groups. The first group includes the mutationsestrogen, progesterone, and testosterone (Figure 6D).
Interestingly, the mineralocorticoids that selectively G507C, M601L, M604P, M646T, Y735S, C736S, and
L753F. In the structure, these residues are found to makebind MR have similar substituents at the C17 position.
MR may also have a similar pocket for these large C17 direct contacts with dexamethasone (green balls, Figure
7A), and their mutations most likely result in a GR mole-substitutes, since the residues that form the GR side
pocket are also conserved in MR. cule that is defective in ligand binding. The second group
includes mutations of P541A, I559D, C638Y, V729I,Besides the shape differences, the polar atoms are
also distributed differently in the steroid pockets with Y764N, and F774A (white balls, Figure 7A). In the struc-
ture, these residues are involved in hydrophobic interac-respect to the specific protein-ligand hydrogen bonds.
For example, the polar substituents in steroid hormones tions within the protein, and their mutations may there-
fore destabilize the protein. The availability of the GRare mainly located at positions C3 or C17. In the GR
structure, the C3 ketone accepts hydrogen bonds from structure provides an opportunity to determine whether
there is any correlation in the locations of these muta-Q570 and R611, which are also conserved in AR and
PR. In ER, the glutamine is replaced by glutamate, which tions with the clinical phenotypes.
prefers to accept a hydrogen bond from the ligand,
therefore accounting for ER’s selectivity of a hydroxyl Structural Basis for the Improvement of Protein
Solubility by the F602S Mutationgroup at the C3 position. These differences in hydrogen
bond formation may explain why GR, as well as AR, PR, It is intriguing that a single point mutation of F602S has
such a dramatic impact on the solubility of the GR LBD.and MR prefer the steroid hormones with a ketone at
the C3 position, whereas ER prefers a hydroxyl group. The F602S mutation was one of fourteen mutations that
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were suggested by sequence alignment and analysis and/or exchange in vivo is dependent on hsp90. More-
of a GR homology model. Most of the mutations were over, the hsp90 complex may also function to prevent
targeted for lipophilic residues exposed on the surface the wild-type GR protein from aggregating in vivo by
of the protein, but had little or no effect on expression maintaining the structural integrity of the otherwise un-
or solubility. In contrast, F602 was identified as a buried, stable protein.
lipophilic residue that appeared to fit poorly into its envi-
ronment within GR. Remarkably, the F602S mutation Experimental Procedures
substantially enhanced the soluble expression of the
Protein PreparationGR LBD. This result is consistent with the earlier work
The GR LBD (residues 521–777), containing a single F602S muta-on the corresponding mutation of the rat GR (F620S),
tion, was expressed in the presence of 10 M dexamethasone as
which showed increased receptor activity and was a 6  His-GST fusion protein from the expression vector pET24a
shown to be less dependent on hsp90 proteins for its (Novagen). The modified fusion protein contains a His-TAG
function (Freeman et al., 2000; Garabedian and Yama- (MKKGHHHHHHG) at the N terminus and a thrombin protease site
between GST and the GR LBD. The GR LBD was purified to homoge-moto, 1992). The GR structure presented here provides
neity using similar procedures previously described for AR and PRa further rationale for the improvement in solubility by
(Matias et al., 2000; Williams and Sigler, 1998). A typical yield of thethe F602S mutation. Although F602 is buried deeply
purified protein is about 1 mg from each liter of cells. To prepareinside of the protein at the first turn of helix-5, where it the protein-ligand-coactivator complex, we added a 2-fold excess
is sandwiched between helices 3 and 10 (Figure 7A), of the TIF2 peptide to the purified GR LBD, which was present with
the hydrophobic side chain of F602 is surrounded by 50 M dexamethasone. The ternary complex was then diluted 10-
fold with a buffer containing 500 mM ammonium acetate, 50 mMa small hydrophilic cavity (Figure 7B). This hydrophilic
Tris, (pH 8.0), 10% glycerol, 10 mM dithiothreitol, 0.5 mM EDTA,cavity is made up of the side chains of S599, S673, S674,
and 0.05% 
-n-octoglucoside, and concentrated to 6.3 mg/ml forand H726, and the backbone carbonyls of residues 598,
crystallization. The I628A/F602 mutant LBD was expressed and puri-599, 670, and 722. The presence of the hydrophobic
fied with the same procedures for the F602S mutant LBD except
phenylalanine side chain in the polar environment would the TIF2 peptide was added during purification.
be highly unfavorable. This arrangement may cause the
local instability that makes the protein prone to aggrega- Crystallization and Data Collection
tion and/or misfolding. The F602S mutation replaces The GR/dexamethasone/TIF2 crystals were grown at room tempera-
the hydrophobic phenyl ring with a small hydrophilic ture in hanging drops containing 3.0 l of the above protein-ligand
solutions, and 0.5 l of well buffer containing 50mM HEPES, (pHhydroxyl group, creating a more suitable arrangement
8.0), and 2.0 M ammonium formate. Crystals appeared overnightwithin the hydrophilic environment, and apparently over-
and continued to grow to a size up to 300 micron within a week.coming the instability problem. In the crystal structure,
Before data collection, crystals were transiently mixed with the well
the volume created by the F602S mutation is filled by buffer containing additional 25% of glycerol, and were then flash
three water molecules. These water molecules not only frozen in liquid nitrogen.
cap the N terminus of helix-5 but also mediate an exten- The GR/TIF2/dexamethasone crystals formed in the P61 space
group, with a  b  126.014 A˚, c  86.312 A˚,   
 90, andsive hydrogen bond network with the residues that make
 120. Each asymmetry unit contains two GR LBDs with 56% ofup the cavity. Interestingly, PR has a serine at the corre-
solvent content. The 2.8 A˚ data set was collected with an in-housesponding position, and most of the other nuclear recep-
Rigaku Raxis IV detector and the 2.5 A˚ data set was collected withtors have a glutumate residue at this position. In the
a MAR CCD detector at 17-ID in the facilities of the Industrial Macro-
structures of other NRs including PPARs, this negatively molecular Crystallography Association (IMCA) at the Advanced Pho-
charged residue forms a pair of hydrogen bonds with a ton Source. The observed reflections were reduced, merged, and
conserved arginine from the loop between helices 8 and scaled with DENZO and SCALEPACK in the HKL2000 package (Ot-
winowski and Minor, 1997).9 (Gampe et al., 2000; Nolte et al., 1998; Xu et al., 1999,
2001). Thus, a hydrophilic residue at position 602 has
Structure Determination and Refinementbeen evolutionarily conserved in other NRs, possibly to
The 2.8 A˚ structure of the GR/dexamethasone/TIF2 complex waspreserve the stability of the protein. GR is the only nu-
determined by molecular replacement with the AmoRe programclear receptor with a large hydrophobic residue at this
(Navaza et al., 1992; Williams and Sigler, 1998; Xu et al., 2001). Theposition, and this may account for the difficulty in ob- initial GR model, containing residues 527–776 of wild-type GR and
taining a stable protein with wild-type GR constructs. residues 740–752 of TIF2, was built with the MVP program by com-
Extensive studies have indicated that ligand binding bining the PR LBD structure (Williams and Sigler, 1998) with the
of GR in vivo or in vitro depends on the presence of the SRC-1 portion of the PPAR/SRC-1 structure (Navaza et al., 1992;
Williams and Sigler, 1998; Xu et al., 2001). Two solutions were ob-hsp90 chaperone complex (Pratt and Toft, 1997). It has
tained from the molecular replacement search with a correlationalso been proposed that hsp90 is required for opening
coefficiency of 43% and an R-factor of 45.3%, consistent with twothe GR ligand binding pocket to allow ligand association
complexes within each asymmetry unit. The phases from the molec-
(Morishima et al., 2000). Interestingly, using our purified ular replacement solution were extensively refined with solvent flat-
protein, the F602S mutant GR LBD is freely accessible tening, histogram matching, and 2-fold noncrystallographic symme-
to agonist and antagonist as demonstrated by the com- try (NCS) averaging as implemented in the CCP4 dm program and
petition experiment (Figures 1B and 1C). In the structure, produced a clear map for the GR LBD, the TIF2 peptide, and the
dexamethasone. Multiple cycles of manual model building, includingthe GR pocket is completely enclosed when it is bound
conversion of side-chains from the SRC-1 and wild-type GR se-with dexamethasone. Exchange of dexamethasone with
quences to the actual TIF2 and GR F602S sequences, respectively,RU486 in the purified protein must involve opening the
was carried out with QUANTA (Accelrys Inc). Structure refinements
pocket even in the absence of hsp90. However, the in vivo proceeded with CNX (Brunger et al., 1998), using the maximum
high-affinity binding of ligands still requires the chaper- likehood target and NCS constraints, which was relaxed in the final
one activity of hsp90 (Bresnick et al., 1989; Picard et stages of refinement. The 2.5 A˚ structure of the GR/dexamethasone/
TIF2 complex was then determined by using the 2.8 A˚ structureal., 1990). It is possible that the rate of ligand binding
Crystal Structure of the Glucocorticoid Receptor
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as the model. The statistics of the structures and data sets are specific volume of the protein, , was calculated as described (Cohn
and Edsall, 1943). Adjustments for temperature were made usingsummarized in Table 1. The 2-fold symmetry axis of the GR dimer
was calculated as axis of the rotation that would superimpose one the appropriate equation that has been modified to use  values
derived for each amino acid at 25C (Durchschlag, 1986). The partialLBD onto the other. The superposition was carried out using the
C atoms from residues 530–777 of GR. Solvent accessible surface specific volume of GR LBD was calculated to be 0.736 mL/g at 4C.
Runs were performed at 17,500, 20,000, 22,500, and 25,000 rpm atareas were calculated with the Connolly MS program and the MVP
program (Connolly, 1983; Lambert, 1997). The pocket volume and 4C. Data sets were obtained as radial distance versus absorbance.
Scans were taken at 280 nm at 1 hr intervals throughout the run.binding site accessible waters were calculated with MVP.
Sedimentation equilibrium was judged by the absence of change
between plots of several successive scans after approximatelyBinding Assays
20–30 hr at each speed. The raw data (from the meniscus to theThe ligand binding activity of the purified GR LBD was determined
back of the cell) was analyzed by an adaptation of the Beckman/by a fluorescence polarization assay. Experiments were conducted
Microcal Origin nonlinear regression software package using multi-by combining 10 nM fluorescence-dexamethasone (Molecular
ple iterations of the Marquardt-Levenberg algorithm for parameterProbes) with increasing concentrations of the purified GR LBD in a
estimation. Multiple models were employed to determine the mostbuffer containing 10 mM HEPES (pH 7.4), 0.15 M NaCl, 3 mM EDTA,
accurate description of the macromolecular species.0.005% polysorbate-20 and 5 mM DTT. The fluorescence polariza-
tion values for each concentration of receptor were determined
Functional Assays of the GR Dimer Interfaceusing a BMG PolarStar Galaxy fluorescence plate reader with 485
Assessment of the functional activity of full-length, wild-type, andnm excitation and 520 nm emission filters. The apparent Kd values
mutant GR constructs was carried out using the transient transfec-were determined with a nonlinear least squares fit of the data for a
tion assay. To assess transactivation, expression vector (pRS vec-simple 1:1 interaction. Note that the apparent affinity for the binding
tor) encoding full-length, wild-type, or mutated GR protein (0.1 ng)of the fluorescent dexamethasone (60 nM) is slightly weaker than
was cotransfected into CV-1 cells with a reporter plasmid (15 ng)previously reported values most likely due to the presence of unla-
containing luciferase under transcriptional control of the GR-respon-beled dexamethasone that remains in the protein preparations de-
sive region in the MMTV promoter (List et al., 1999). To assessspite extensive dialysis.
transrepression, GR expression vectors (5 ng) were cotransfectedThe binding of the TIF2 coactivator motif to the GR LBD was
with pCMV-4T expression vector (0.1 ng) encoding p65 NF-B sub-determined by surface plasmon resonance using a Biacore 3000
unit, and a reporter plasmid (10 ng) containing a fragment of theinstrument. Experiments were conducted at 25C with 500 RU
NF-B-responsive MCP-1 promoter (Ping et al., 1999). CV-1 cellsbiotinylated TIF2 peptide bound onto a streptavidin chip. Running
were transiently transfected with lipofectamine (Invitrogen, Inc.) asbuffer (10 mM HEPES [pH 7.4], 150 mM NaCl, 3 mM EDTA, 0.005%
described (Moore et al., 2000; Willson et al., 1996). Cells were treatedpolysorbate-20, and 5 mM DTT) was used with a flow rate of 5 l/
with 100 nM dexamethasone on day 2 of the transfection proceduremin. Binding signals were determined by injecting varied concentra-
and reporter activity assessed at day 3. Luciferase activity wastions of the GST-GR LBD (F602S) with no added ligand, 5-fold molar
normalized using an internal constitutively active reporter to controlexcess of dexamethasone, or RU486. A dose-response curve was
for well-to-well variation. Data were plotted as fold activation byconstructed using the equilibrium response taken 10 s before the
dexamethasone after subtracting background activity of CV-1 cellsend of the association phase minus the response from a flow cell
transfected in the absence of added receptor.with no immobilized peptide.
The effects of the R2H and D6Q mutations in the TIF2 third
In Vivo Assays of the Second Charge Clamp Mutationsmotif on the binding to GR, PR, AR, and ER
 were determined by
The effect of the primary and secondary charge clamp mutationschemical mediated energy transfer assays using the AlphaScreen
on activation in vivo was determined using a Gal4 transactivationTechnology from Packard BioScience, as described recently for
assay. The wild-type GR LBD (486–777) or mutated GR LBD wasnuclear receptors (Xu et al., 2002). Proteins were prepared by ex-
fused in frame with the Gal4 DBD in a mammalian expression vectorpressing the AR LBD (residues 662–919), the PR LBD (residues
(pSG5). The Gal4 DBD-GR LBD fusion vector (8 ng) was cotrans-678–933), and the GR LBD (residues 521–777 with F602S) as 6 
fected into CV-1 cells with a reporter plasmid pUAS-TK (8 ng) con-His-GST fusion proteins in the presence of the respective ligands
taining luciferase under transcriptional control of the Gal4-respon-R1881, progesterone, and dexamethasone. The ER
 LBD (residues
sive region. CV-1 cells were transiently transfected as previously257–530) was prepared in the absence of ligand. These proteins
described with the exception of Fugene 6 (Roche) as the transfectionwere partially purified by Ni 2 chromatography. The experiments
reagent.were conducted with approximately 2 nM receptor LBD, 4 nM of
biotinylated peptide containing the TIF2 third motif in a buffer con-
taining 50 mM MOPS (pH 7.4), 50 mM NaF, 0.05 mM CHAPS, 0.1 Western Blotting
mg/ml bovine serum albumin, and 5 mM dithiothreitol. An excess Equal amounts of total cellular protein were electrophoresed on 12%
amount of 1 M R1881, progesterone and dexamethasone, and SDS-PAGE and transferred to Trans-Blot nitrocellulose membranes
estradiol was added to AR, PR, GR, and ER
, respectively. An (BioRad, Hercules, CA). GR was visualized using an ECL detection
AlphaScreen hexahistidine detection kit was utilized and the donor system (Amersham Pharmacia Biotech, Piscataway, NY) after incu-
and acceptor bead concentrations were 8g/ml. The binding signals bation with rabbit polyclonal antibody (anti-human GR, sc-1002
were obtained with increasing concentrations of the unlabeled third Santa Cruz Biotechnology, Santa Cruz, CA) and a horseradish per-
motif peptide or the mutated peptide and detected using a Packard oxidase-linked goat anti-mouse secondary antibody (Southern Bio-
BioScience AlphaQuest HTS. The IC50 values were constructed tech Associates, Birmingham, AL).
from a nonlinear least squares fit of the data for a simple 1:1 interac-
tion and are an average of four repeated experiments with DMSO Acknowledgments
as controls.
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